| Period Ending: | 2025 12-31 |
2024 12-31 |
2023 12-31 |
2022 12-31 |
2021 12-31 |
2020 12-31 |
2019 12-31 |
2018 12-31 |
|---|---|---|---|---|---|---|---|---|
| Total |
1234
|
|||||||
| Grant |
1234
|
|||||||
| Grant (%) |
1234
|
|||||||
| Collaboration Revenue |
1234
|
|||||||
| Collaboration Revenue (%) |
1234
|
|||||||
| Exclusive License |
1234
|
|||||||
| Exclusive License (%) |
1234
|
|||||||
| Myotonic Dystrophy Type One License |
1234
|
|||||||
| Myotonic Dystrophy Type One License (%) |
1234
|
|||||||
| Collaborative Arrangement Material Rights Fourth Exclusive License |
1234
|
|||||||
| Collaborative Arrangement Material Rights Fourth Exclusive License (%) |
1234
|
|||||||
| Collaborative Arrangement Material Rights |
1234
|
|||||||
| Collaborative Arrangement Material Rights (%) |
1234
|
|||||||
| Duchenne Muscular Dystrophy License |
1234
|
|||||||
| Duchenne Muscular Dystrophy License (%) |
1234
|
|||||||
| Myotonic Dystrophy Type One R And D Services |
1234
|
|||||||
| Myotonic Dystrophy Type One R And D Services (%) |
1234
|
|||||||
| Specified Target Option Material Right |
1234
|
|||||||
| Specified Target Option Material Right (%) |
1234
|
|||||||
| Waiving Of Vertexs Material Right |
1234
|
|||||||
| Waiving Of Vertexs Material Right (%) |
1234
|
|||||||
| License And Service |
1234
|
|||||||
| License And Service (%) |
1234
|
|||||||
